The complete structure of saliva receptor has been revealed by scientists.
At the molecular level, drugs like salvinorin A (the active ingredient of the hallucinogenic plant Salvia divinorum) work by activating specific proteins, known as receptors, in the brain and body.
Salvinorin A, the most potent naturally occurring hallucinogen, is unusual in that it interacts with only one receptor in the human brain - the kappa opioid receptor (KOR).
In a research paper, scientists from the University of North Carolina at Chapel Hill, Scripps Research Foundation and two other institutions divulged the first-ever glance of the complete structure of the KOR.
The finding could accelerate the development of new drugs to treat addiction, depression, anxiety, chronic pain and many other conditions.
"Once we see the structure of the receptor, it becomes easier for us to develop drugs that target the receptor in ways that might be beneficial for medical therapy," said Bryan Roth, MD, PhD, the Michael Hooker Distinguished Professor of Pharmacology at UNC and one of the paper's authors.
"Drugs that block the receptor are potentially useful for treating a number of serious illnesses including chronic pain, cocaine addiction and other diseases."
Knowing KOR's structure offers insights about how salvia and other drugs work. The finding also could help scientists design medicines that either activate or block KOR to benefit patients.
The research team crystallized KOR using JDTic, a drug currently in early-stage human trials; JDTic keeps KOR in an inactive state and blocks the actions of salvinorin A.
In studies using animal models, JDTic has shown promise for treating cocaine and nicotine addiction, depression and anxiety.
The downside of JDTic and similar drugs targeting KOR is that they can exert their actions for weeks, whereas most prescribed medicines are cleared within 18-24 hours.
"Now that we have the [KOR] structure, it opens up the possibility for us to make drugs that have the same action as JDTic but have better pharmaceutical properties," said Roth.
The research also resolves longstanding scientific debates about how drugs bind to KOR. The study found that compared to other receptors, the binding site on KOR is enormous, allowing drugs to bind to it in more than one way.
In addition, Roth said the research could help scientists develop drugs that activate KOR in the body without affecting the brain, which could be useful for treating chronic pain, kidney problems and many other disorders.
The study has been published in the journal Nature.